{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Phathom Pharmaceuticals, Inc.
Is Phathom Pharmaceuticals, Inc. technically bullish or bearish?
As of October 31, 2025, Phathom Pharmaceuticals shows a bullish trend supported by positive MACD and Bollinger Bands, but mixed signals from KST and a year-over-year decline of 24.85% suggest cautious optimism despite a strong year-to-date return of 69.09%.
Is Phathom Pharmaceuticals, Inc. technically bullish or bearish?
As of October 31, 2025, Phathom Pharmaceuticals, Inc. shows a bullish technical trend with strong momentum indicators, despite mixed signals from KST and Dow Theory, and has outperformed the S&P 500 year-to-date, although it has declined over the past year.
Is Phathom Pharmaceuticals, Inc. technically bullish or bearish?
As of October 31, 2025, Phathom Pharmaceuticals, Inc. shows a bullish technical trend, supported by positive MACD and Bollinger Bands signals, despite some bearish indications from the KST, with a year-to-date return of 66.87% compared to the S&P 500's 16.30%.
Phathom Pharmaceuticals, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
Phathom Pharmaceuticals, Inc. has recently revised its evaluation amid market dynamics, with its stock price showing a slight increase. The company has experienced significant volatility over the past year, with notable returns year-to-date, outperforming the S&P 500. Technical indicators present a mixed outlook on momentum.
Is Phathom Pharmaceuticals, Inc. technically bullish or bearish?
As of October 24, 2025, Phathom Pharmaceuticals, Inc. shows a bullish technical trend with positive momentum indicators, despite some bearish signals in the KST, and has significantly outperformed the S&P 500 year-to-date, although it lags behind over longer time frames.
Is Phathom Pharmaceuticals, Inc. technically bullish or bearish?
As of October 24, 2025, Phathom Pharmaceuticals, Inc. shows a bullish technical trend supported by positive MACD and Bollinger Bands, though caution is advised due to mildly bearish KST signals.
Is Phathom Pharmaceuticals, Inc. technically bullish or bearish?
As of October 24, 2025, Phathom Pharmaceuticals, Inc. shows a bullish trend supported by daily moving averages and weekly Bollinger Bands, despite mixed signals from the KST and a decline in long-term performance compared to the S&P 500.
Phathom Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics
Phathom Pharmaceuticals, Inc. has recently revised its evaluation amid market fluctuations, with its stock price at $12.96. The company has experienced significant volatility over the past year, with a 52-week high of $19.50 and a low of $2.21. Recent trends suggest a potential recovery phase.
Phathom Pharmaceuticals Hits Day High with 7.6% Surge in Stock Price
Phathom Pharmaceuticals, Inc. has seen significant short-term gains, with a notable increase today and a strong weekly performance. Despite a challenging one-year outlook, the company has rebounded year-to-date. It has a market capitalization of USD 882 million and high institutional ownership, but faces financial risks.
Phathom Pharmaceuticals Hits Day Low of $10.33 Amid Price Pressure
Phathom Pharmaceuticals, Inc. saw a notable decline in its stock price, contrasting with the S&P 500's modest gain. Over the past year, the stock has significantly underperformed the market, despite a positive year-to-date return. The company's financial metrics indicate challenges ahead in the competitive pharmaceuticals sector.
Phathom Pharmaceuticals Experiences Evaluation Revision Amid Mixed Performance Indicators
Phathom Pharmaceuticals, Inc. has recently revised its evaluation amid market fluctuations. The stock is currently priced at $11.78, reflecting significant volatility over the past year. While it has outperformed the S&P 500 year-to-date, its one-year and five-year performances show notable declines compared to the index.
Is Phathom Pharmaceuticals, Inc. technically bullish or bearish?
As of September 5, 2025, Phathom Pharmaceuticals, Inc. shows a bullish trend with strong daily moving averages and a bullish weekly MACD, despite a bearish monthly RSI; the stock has gained 16.34% in the past month but has a 1-year return of -38.90%, underperforming the S&P 500.
Is Phathom Pharmaceuticals, Inc. overvalued or undervalued?
As of May 9, 2024, Phathom Pharmaceuticals, Inc. is considered risky and overvalued due to negative valuation ratios and a one-year return of -38.90%, despite a strong YTD return of 44.70% that outperformed the S&P 500.
Is Phathom Pharmaceuticals, Inc. overvalued or undervalued?
As of May 9, 2024, Phathom Pharmaceuticals, Inc. is rated as risky and overvalued, with concerning financial metrics and a 1-year return of -14.53%, significantly underperforming the S&P 500's 10.26%.
Is Phathom Pharmaceuticals, Inc. technically bullish or bearish?
As of June 18, 2025, the technical trend is neutral with mixed signals, as weekly indicators show bullish momentum while monthly indicators are bearish, resulting in a lack of clear direction.
Who are in the management team of Phathom Pharmaceuticals, Inc.?
As of March 2022, the management team of Phathom Pharmaceuticals, Inc. includes Dr. Tadataka Yamada (Independent Chairman), Ms. Terrie Curran (President and CEO), and Mr. David Socks (CFO). The Board also features independent directors such as Mr. Michael Cola and Ms. Heidi Kunz.
What does Phathom Pharmaceuticals, Inc. do?
Phathom Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases. As of March 2025, it reported net sales of $29 million and a net loss of $94 million, with a market cap of $733.05 million.
How big is Phathom Pharmaceuticals, Inc.?
As of Jun 18, Phathom Pharmaceuticals, Inc. has a market capitalization of 733.05 million and reported net sales of 81.85 million with a net profit of -345.80 million over the latest four quarters. Shareholder's funds are -253.58 million, and total assets are 378.47 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
